Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 3/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 8/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29493385 | 0.83 | SMYD3 (0.43) | SMYD3PTGDR2 | |
| SCHEMBL30745941 | 0.82 | P2RY12 (0.39) | SMYD3MTORP2RY12PPARGPPARA | |
| SCHEMBL30613801 | 0.81 | P2RY12 (0.42) | P2RY12 | |
| SCHEMBL25341749 | 0.81 | MTOR (0.50) | MTORPDE10AP2RX7 | |
| SCHEMBL30613774 | 0.77 | TSHR (0.43) | PDE10A | |
| SCHEMBL30613770 | 0.74 | MTOR (0.38) | SMYD3MTORP2RY12PTGDR2 | |
| SCHEMBL30613818 | 0.74 | MTOR (0.38) | SMYD3MTORPTGDR2 | |
| SCHEMBL31623568 | 0.74 | SMYD3 (0.45) | SMYD3PDE10APTGDR2 | |
| SCHEMBL13249799 | 0.74 | TP53 (0.40) | SMYD3P2RY12PPARGPPARAPTGDR2 | |
| SCHEMBL25342146 | 0.73 | MEN1 (0.44) | PDE10AP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516064-B2 | Tetrahydropyridopyrimidines and related analogs for inhibiting YAP/TAZ-TEAD | SpringWorks Therapeutics Inc. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20240018148-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018148-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | YAP1, TEAD2, TEAD1 | SMYD3 1812/4885MTOR 574/4885P2RY12 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.